MARKET

PCRX

PCRX

Pacira Biosciences Inc
NASDAQ
25.90
-0.91
-3.39%
After Hours: 25.90 0 0.00% 16:02 04/24 EDT
OPEN
26.65
PREV CLOSE
26.81
HIGH
26.77
LOW
25.78
VOLUME
359.41K
TURNOVER
0
52 WEEK HIGH
48.60
52 WEEK LOW
25.74
MARKET CAP
1.20B
P/E (TTM)
29.22
1D
5D
1M
3M
1Y
5Y
Noteworthy Tuesday Option Activity: PCRX, CMG, CVNA
NASDAQ · 1d ago
Weekly Report: what happened at PCRX last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at PCRX last week (0408-0412)?
Weekly Report · 04/15 09:11
Pacira BioSciences (NASDAQ:PCRX) sheds US$55m, company earnings and investor returns have been trending downwards for past three years
Pacira BioSciences, Inc. (NASDAQ:PCRX) share price is down 60% over three years. The share price has fallen 33% in the last year, and is down 15% in a quarter. The company's earnings per share has dropped by 36% over the same period. The market may not be concerned about the drop in the share price, but is the company growing revenue? We look at whether there's a mismatch between the fundamentals and share price.
Simply Wall St · 04/11 12:39
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 6 Analysts
Pacira BioSciences is a provider of non-opioid pain management and regenerative health solutions. 6 analysts have shared their insights on Pacira Biosciences in the last three months. The company has an average price target of $49.0. The 12-month price targets assessed by analysts are lower than the previous average of $57.00.
Benzinga · 04/09 14:00
Pacira BioSciences Price Target Maintained With a $45.00/Share by Needham
Dow Jones · 04/09 10:26
Needham Reiterates Buy on Pacira BioSciences, Maintains $45 Price Target
Benzinga · 04/09 10:16
Understanding Key Factors Behind Pacira Pharmaceuticals’ Analyst Rating
TipRanks · 04/09 10:16
More
About PCRX
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.

Webull offers Pacira Biosciences Inc stock information, including NASDAQ: PCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PCRX stock methods without spending real money on the virtual paper trading platform.